Article

The CCL2-CCR2 axis contributes to acquired osimertinib resistance in lung cancer by upregulating Zeb1 expression

2023-12-01

Abstract excerpt

<title>Abstract</title> <p>Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), effectively treats non-small-cell lung cancer patients with EGFR activation mutations or those with acquired T790M resistance mutation following EGFR-TKIs therapy. However, the development of drug resistance remains a significant clinical challenge. Therefore, we aimed to investigate...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ab0bc7fc-4aa7-54e6-afd2-073b87f809ea
DOI: 10.21203/rs.3.rs-3674324/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The CCL2-CCR2 axis contributes to acquired osimertinib resistance in lung cancer by upregulating Zeb1 expressionDOI 10.21203/rs.3.rs-3674324/v1Read

Bulk RNA analysis identified the characteristics and immunoinvasive patterns of osimertinib resistance in patients with non-small cell lung cancerSemantic proximity Read

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.Semantic proximity Read

Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells.Semantic proximity Read

Interleukin-1α-Mediated Activation of TNF-α/NF-κB Signaling Confers Resistance to Osimertinib in EGFR-Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read

MicroRNA-130a-3p regulates osimertinib resistance by targeting runt-related transcription factor 3 in lung adenocarcinomaSemantic proximity Read

Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization.Semantic proximity Read

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer CellsSemantic proximity Read

AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer.Semantic proximity Read

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer.Semantic proximity Read

Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targetingSemantic proximity Read

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.Semantic proximity Read

SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemnessSemantic proximity Read